KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash & Equivalents (2016 - 2025)

Edwards Lifesciences has reported Cash & Equivalents over the past 17 years, most recently at $2.9 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $2.9 billion for Q4 2025, down 3.52% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (down 3.52% YoY), and the annual figure for FY2025 was $2.9 billion, down 3.52%.
  • Cash & Equivalents for Q4 2025 was $2.9 billion at Edwards Lifesciences, up from $2.7 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for EW hit a ceiling of $3.7 billion in Q3 2024 and a floor of $11.7 million in Q4 2023.
  • Median Cash & Equivalents over the past 5 years was $1.3 billion (2021), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Cash & Equivalents: plummeted 98.46% in 2023 and later surged 25927.35% in 2024.
  • Edwards Lifesciences' Cash & Equivalents stood at $862.8 million in 2021, then decreased by 11.74% to $761.5 million in 2022, then plummeted by 98.46% to $11.7 million in 2023, then surged by 25927.35% to $3.0 billion in 2024, then fell by 3.52% to $2.9 billion in 2025.
  • The last three reported values for Cash & Equivalents were $2.9 billion (Q4 2025), $2.7 billion (Q3 2025), and $3.3 billion (Q2 2025) per Business Quant data.